State DC
Clinical Trials in Washington D.C.
Recruiting clinical trials with at least one study location in Washington D.C.. Data updated daily from ClinicalTrials.gov.
Top Conditions in Washington D.C.
Malignant Solid Neoplasm (5)Alzheimer Disease (4)Prostate Cancer (3)Solid Tumor (3)Ewing Sarcoma (3)Hepatocellular Carcinoma (3)Myeloproliferative Neoplasm (2)Acute Treatment of Migraine (2)Asthma in Children (2)Hematopoietic and Lymphatic System Neoplasm (2)Acute Lymphoblastic Leukemia (2)Acute Myeloid Leukemia (2)
NCT05661201 Phase 1
Recruiting
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Condition
Solid Tumor
Enrollment
24 pts
Location
United States
Sponsor
Georgetown University
NCT05803941 Phase 4
Recruiting
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With ...
Condition
Prostate Cancer
Enrollment
700 pts
Location
United States, Austria, Belgium
Sponsor
Novartis Pharmaceuticals
NCT06568237 Phase 2
Recruiting
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Mul...
Condition
Multiple System Atrophy
Enrollment
350 pts
Location
United States, France, Germany
Sponsor
Teva Branded Pharmaceutical Pr
NCT06679140 Phase 3
Recruiting
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolesc...
Condition
COVID-19 SARS-CoV-2 Infection
Enrollment
2,330 pts
Location
United States, Argentina, Belgium
Sponsor
Pfizer
NCT06840483 Phase 2
Recruiting
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
Condition
Breast Cancer
Enrollment
66 pts
Location
United States, Australia, Belgium
Sponsor
BicycleTx Limited
NCT05894239 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Ph...
Condition
Metastatic Breast Cancer
Enrollment
230 pts
Location
United States, Argentina, Australia
Sponsor
Hoffmann-La Roche
NCT07104383 Phase 3
Recruiting
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
Condition
Weight Loss
Enrollment
1,100 pts
Location
United States, Puerto Rico
Sponsor
Viking Therapeutics, Inc.
NCT05871970 Phase 2
Recruiting
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic...
Condition
Lymphatic Malformation
Enrollment
38 pts
Location
United States
Sponsor
Protara Therapeutics
NCT04927429 N/A
Recruiting
Technical Development of Cardiovascular Magnetic Resonance Imaging
Condition
Cardiovascular Disease
Enrollment
3,400 pts
Location
United States
Sponsor
National Heart, Lung, and Bloo
NCT06136650 Phase 3
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Age...
Condition
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment
1,314 pts
Location
United States, Australia, Brazil
Sponsor
Merck Sharp & Dohme LLC
NCT05580562 Phase 3
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study...
Condition
H3 K27M
Enrollment
450 pts
Location
United States, Argentina, Australia
Sponsor
Jazz Pharmaceuticals
NCT05734066 Phase 1, Phase 2
Recruiting
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants Wit...
Condition
Refractory Ewing Sarcoma
Enrollment
60 pts
Location
United States, Canada
Sponsor
Jazz Pharmaceuticals
NCT07257029 Phase 2
Recruiting
Topical Ketotifen 0.25% for Secondary Vestibulodynia
Condition
Provoked Vestibulodynia
Enrollment
54 pts
Location
United States
Sponsor
Center for Vulvovaginal Disord
NCT05868629 N/A
Recruiting
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In...
Condition
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
Enrollment
40 pts
Location
United States
Sponsor
Novartis Pharmaceuticals
NCT05855200 Phase 3
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage ...
Condition
Colonic Neoplasms
Enrollment
892 pts
Location
United States, Argentina, Australia
Sponsor
GlaxoSmithKline
NCT06398639 N/A
Recruiting
Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevan...
Condition
Prostate Cancer
Enrollment
1,500 pts
Location
United States
Sponsor
Adam S. Kibel, MD
NCT03587272 Phase 2
Recruiting
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children ...
Condition
Sickle Cell Disease
Enrollment
100 pts
Location
United States, Canada
Sponsor
Robert Nickel
NCT05985161 Phase 2
Recruiting
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Condition
Wilms Tumor
Enrollment
45 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance
NCT05230173 N/A
Recruiting
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remi...
Condition
Ulcerative Colitis
Enrollment
250 pts
Location
United States
Sponsor
University of California, San
NCT06662786 Phase 3
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or ...
Condition
Colorectal Neoplasms
Enrollment
1,000 pts
Location
United States, Belgium, Brazil
Sponsor
Janssen Research & Development
NCT05458674 Phase 2
Recruiting
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
Condition
Breast Cancer
Enrollment
30 pts
Location
United States
Sponsor
Criterium, Inc.
NCT06193759 Phase 1
Recruiting
Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular T...
Condition
Medulloblastoma, Childhood
Enrollment
12 pts
Location
United States
Sponsor
Children's National Research I
NCT05849662 Phase 1, Phase 2
Recruiting
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnos...
Condition
Leukemia, Juvenile Myelomonocytic
Enrollment
58 pts
Location
United States
Sponsor
Therapeutic Advances in Childh
NCT06465810 N/A
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Condition
Transthyretin Amyloidosis
Enrollment
1,850 pts
Location
United States, Canada, China
Sponsor
AstraZeneca
NCT04293562 Phase 3
Recruiting
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilterit...
Condition
Acute Myeloid Leukemia
Enrollment
1,186 pts
Location
United States, Australia, Canada
Sponsor
Children's Oncology Group